The U.S. Food and Drug Administration authorized a single‑patient expanded‑access (compassionate‑use) IND for OKYO Pharma’s investigational eye therapy urcosimod on January 23, 2026. The authorization, granted under IND 176297, allows the company to supply a 0.05% urcosimod formulation to a patient suffering from severe neuropathic corneal pain who has no approved treatment options.
The approval marks a significant regulatory milestone for OKYO, underscoring the unmet need for topical therapies in neuropathic corneal pain (NCP). Urcosimod’s dual anti‑inflammatory and pain‑relieving mechanisms—targeting the ChemR23 receptor—have shown promise in pre‑clinical models and a prior Phase 2 trial that demonstrated meaningful pain reduction. CEO Robert J. Dempsey said the compassionate‑use authorization “highlights the pressing global need for innovative therapies to specifically address neuropathic corneal pain and offers a new hope for patients who currently have no FDA‑approved options.”
The compassionate‑use approval also provides OKYO with real‑world data that can inform the design of its planned 120‑patient Phase 2b/3 multiple‑dose study, slated for later this year. By demonstrating safety and tolerability in a real‑world setting, the company can strengthen its regulatory dossier and potentially accelerate the drug’s path to full approval. The milestone aligns with OKYO’s strategy to leverage its Fast‑Track designation and to build a robust evidence base for a disease area with a sizable, underserved patient population.
The announcement comes amid a broader context of limited therapeutic options for NCP; no FDA‑approved drugs exist for this condition, and off‑label treatments often provide only modest relief. OKYO’s CEO transition earlier in January—when Robert Dempsey succeeded Gary S. Jacob—signals a renewed focus on commercialization and strategic growth. While the company remains pre‑revenue, the compassionate‑use authorization is a positive signal to investors and could improve the company’s valuation prospects as it moves closer to a potential market entry.
Analysts have noted a cautious stance toward OKYO, citing the company’s pre‑revenue status and the need for further clinical data. Nevertheless, the FDA’s approval of compassionate use is viewed as a constructive step that may enhance investor confidence in the company’s pipeline and its ability to navigate regulatory pathways for a high‑need indication.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.